Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1344 • 2019 ACR/ARP Annual Meeting
Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study
Eric Toussirot¹, Hubert Marotte ², denis Mulleman ³, gregoire Cormier ⁴, fabienne Coury-Lucas ⁵, Philippe Gaudin ⁶, Emmanuelle Dernis ⁷, christine bonnet ⁸, richard damade ⁹, jean-luc Grauer ¹⁰, Tassadit Ait Abdesselam ¹¹, caroline Karras ¹², frederic Liote ¹³, Pascal Hilliquin ¹⁴, antoinette sacchi ¹⁵, Jean-Marie Berthelot ¹⁶, marc puyraveau ¹ and gilles dumoulin ¹, ¹University Hospital, Besancon, France, ²University Hospital, St Etienne, France, ³University hospital, Tours, France, ⁴CHD Vendée, La Roche sur Yon, France, ⁵University Hospital, Lyon, France, ⁶Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ⁷Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ⁸University Hospital, Limoges, France, ⁹Centre Hospitalier, Chartres, France, ¹⁰Centre Hopsitalier, Montelimar, France, ¹¹Centre Hospitalier, Meaux, France, ¹²Hôpital Saint Joseph, Marseille, France, ¹³AP-HP, Paris, France, ¹⁴Centre Hospitalier, Corbeil Essones, France, ¹⁵Centre Hospitalier, Mantes la Jolie, France, ¹⁶University Hospital, Nantes, France
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) diseases. Dyslipidemia is a known adverse reaction to tocilizumab (TCZ). TNFa blockade…
Abstract Number: 1371 • 2019 ACR/ARP Annual Meeting
Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)
Rong Mu¹, Chun Li ², Jing Yang ³, Xiaohan Wang ⁴, Bin Wu ⁵, Fengxiao Zhang ⁶, Yong Wang ⁷, Li Qin ⁸, Cundong Mi ⁹, Huifang Guo ¹⁰, Wei Wei ¹¹, Wei Liu ¹², Qingchun Huang ¹³, Jing Lu ¹⁴, Yang Liu ¹⁵, Huiling Li ¹⁶, Bing Wu ¹⁷, Hui Xiao ¹⁸, Yuhua Jia ¹⁹ and Fei Xiao ²⁰, ¹People's Hospital, Beijing University Medical School, Beijing, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³Central Hospital of MianYang, Mianyang, Sichuan, China (People's Republic), ⁴Anyang district hospital, Fuyang, Hainan, China (People's Republic), ⁵Chongqing Hospital of Traditional Chinese Medicine, Chongqing, Chongqing, China (People's Republic), ⁶Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), ⁷The first Hospital Affiliated to AMU (Southernwest Hospital), Chongqing, China (People's Republic), ⁸The No.3 People’s Hospital of HuZhou City, Huzhou, Zhejiang, China (People's Republic), ⁹The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ¹⁰The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic), ¹¹Tianjin Medical University General Hospital, Tianjin, Tianjin, China (People's Republic), ¹²First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China (People's Republic), ¹³The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ¹⁴First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China (People's Republic), ¹⁵Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, Nei Mongol, China (People's Republic), ¹⁶Hubei Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China (People's Republic), ¹⁷Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd, shanghai, Shanghai, China (People's Republic), ¹⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic)
Background/Purpose: Daily health care deals with a wide spectrum of RA patients from statuses of remission (R) to disease activities at low (L), moderate (M)…
Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Paul Bird¹, Geoffrey Littlejohn ², Belinda Butcher ³, Tegan Smith ⁴, Candida da Fonseca Pereira ⁵, David Witcombe ⁵ and Hedley Griffiths ⁶, ¹Optimus Research, Kogarah, New South Wales, Australia, ²Monash Rheumatology, Clayton, Victoria, Australia, ³WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁴OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, ⁵Pfizer Australia, Sydney, New South Wales, Australia, ⁶Barwon Rheumatology Service, Geelong, Victoria, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Naonori Tsuda¹, Shigeko Inokuma ², Kenichi Hiraga ³, Yoshinori Masui ³ and Toshikazu Kano ³, ¹Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, ²Chiba Central Medical Center, Ichikawa, Chiba, Japan, ³Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan
Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
Abstract Number: 1888 • 2019 ACR/ARP Annual Meeting
Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
Emma de Moel¹, Jürgen Rech ², Michael Mahler ³, Johannes Roth ⁴, Anne Schouffoer ⁵, Karel Ronday ⁶, Thomas Huizinga ⁵, CF Allaart ⁷, René Toes ⁵, Georg Schett ⁸ and Diane van der Woude ¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ³Inova Diagnostics, San Diego, CA, ⁴University of Muenster, Muenster, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Haga Ziekenhuis, The Hague, Netherlands, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁸Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: The ability to accurately predict whether RA patients will flare following DMARD-tapering would open doors in clinical decision-making for achieving drug-free remission (DFR). Calprotectin…
Abstract Number: 2003 • 2019 ACR/ARP Annual Meeting
Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
JIAWEI XIE¹ and HUI DAI ¹, ¹Peking University, Beijing, China (People's Republic)
Background/Purpose: Anti-polygalacturonic acid antibody (PGA-Ab) is a new rheumatoid arthritis (RA)-related autoantibody first identified by our group. The sensitivity and specificity of PGA-Ab is even…
Abstract Number: 2159 • 2019 ACR/ARP Annual Meeting
Pachymeningitis in Rheumatic Disease
Rachel Kneeland¹, John Berry ², Sydney Brandwein ² and Monika Starosta ², ¹Department of Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, ²Advocate Lutheran General Hospital, Park Ridge, IL
Background/Purpose: Pachymeningitis is a rare complication of rheumatic disease. Patients present with hearing loss or other neurologic complications. Diagnosis is made by thickening of dura…
Abstract Number: 2300 • 2019 ACR/ARP Annual Meeting
Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty
Kyle Morse ¹, Jeremy Abolade ¹, Nicole Heinz ¹, Meng Zhang ², Linda Russell ¹, Serene Mirza ¹, Dana Orange ³, Joshua Wright-Chisem ¹, Mark Figgie ⁴, Peter Sculco ¹ and Susan Goodman⁵, ¹Hospital for Special Surgery, New York, ²The Feinstein Institute for Medical Research, Northwell Health, Manhasset, ³Rockefeller University, New York, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ⁵Hospital For Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Utilization of total hip (THA) and total knee arthroplasty (THA) remains high for patients with RA, and most patients have moderate to high disease…
Abstract Number: 2322 • 2019 ACR/ARP Annual Meeting
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Kimberly Liang¹, Yaming Li ¹, Suresh Mulukutla ¹, Steven Reis ¹, Marc Levesque ¹, Donald Jones ¹, Rachel Gartland ¹, Jennifer Avolio ¹, Ali Hakim Shoushtari ¹, Flordeliza Villanueva ¹, Larry Moreland ¹ and Douglas Landsittel ², ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, RI
Background/Purpose: Both traditional cardiovascular (CV) risk factors and disease-related factors contribute to the increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). Mechanisms of…
Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Scott Matson¹, Kevin Deane ², Christopher Collora ¹, Xi Zheng ¹, Marie Fester ¹, Joyce Lee ¹ and M. Kristen Demoruelle ³, ¹University of Colorado, Denver, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…
Abstract Number: 2366 • 2019 ACR/ARP Annual Meeting
Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Switch to Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Barton Jones ², Allison Petrilla ², Leticia Ferri ³, Xue Han ³ and Kaleb Michaud ⁴, ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with RA experienced an increase in the whole-body insulin sensitivity and a reduction in HbA1c levels from treatment with abatacept, which is a…
Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Takayasu Ando¹, Takeshi Suzuki ², Yutaka Gotou ¹ and Kimito Kawahata ³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
Abstract Number: 2793 • 2019 ACR/ARP Annual Meeting
Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives
Elizabeth Salt¹, Mary Kay Rayens ², Leslie Crofford ³ and Jamie Studts ², ¹University of Kentucky, Lexington, KY, ²University of Kentucky, Lexington, ³Vanderbilt University, Nashville
Background/Purpose: An estimated 11% to 33% of persons taking methotrexate for rheumatoid arthritis (RA) are reported to be at least moderately intolerant to this medication.…
Abstract Number: 2890 • 2019 ACR/ARP Annual Meeting
The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Mark Tatangelo¹, George Tomlinson ², Edward Keystone ³, Michael Paterson ⁴, Nick Bansback ⁵ and Claire Bombardier ⁶, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Toronto, ON, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Institute for Clinical Evaluative Sciences, Toronto, Canada, ⁵University of British Columbia, Vancouver, Canada, ⁶Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The direct and indirect effects of rheumatoid arthritis (RA) are difficult to measure in observational studies because: (1) The inflammatory effects of RA are…
Abstract Number: 222 • 2018 ACR/ARHP Annual Meeting
Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence
Fatima Kudaeva¹, Janet E. Pope² and Mark Speechley³, ¹Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²Department of Medicine, University of Western Ontario, London, ON, Canada, ³Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex etiology. Infections are viewed as environmental triggers of RA. Different viral exposures have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].